Search

everythinglearnresearchcommunity

for

Search:↓

A new product, Minoxidil booster, which enhances sulfotransferase enzyme activity in the scalp, is now available. The user has started using this product, applied before Minoxidil, to improve their hair loss treatment results.

KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.

The conversation discusses a person's hair loss treatment over 1.1 years with finasteride, 1.5 years with minoxidil, and 2 months of microneedling, noting less shedding since starting vitamin D3 a month ago. Commenters are impressed with the results.

The user experienced significant hair regrowth using a regimen of minoxidil 5% twice daily, finasteride 1 mg daily, microneedling, ketoconazole 2% twice a week, and occasional castor and coconut oil, along with daily scalp massages. They are optimistic about reversing their Norwood 5/6 hair loss.

GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.

The user used finasteride but stopped due to side effects, then used topical minoxidil for 13 months, and later added KX826/pyrilutamide for 8 months. They experienced shedding after starting pyrilutamide and use minoxidil and KX826 once daily.

The user is considering switching from an expensive topical hair loss treatment containing 8% Minoxidil, 0.3% Finasteride, Retinoic Acid, and Hydrocortisone to a cheaper Kirkland brand Minoxidil. They are concerned about the effectiveness of the lower concentration and the absence of additional ingredients.

The user is using Minoxidil, Finasteride, microneedling, and plans to add low-level laser therapy (LLLT) to treat hair thinning. They shared progress pictures showing results from May 8th to June 7th.

Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hair follicle regeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regenerated follicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hair regeneration.

A 21-year-old is using 5mg Minoxidil, 1mg Dutasteride, Nizoral, and occasional microneedling for hair loss, seeing improvement on the left side of the scalp. They stopped microneedling due to scalp inflammation and are awaiting a dermatologist appointment.

A 22-year-old male has been using oral minoxidil, oral finasteride, microneedling, and ketoconazole for hair loss treatment over two years, experiencing some regrowth and maintenance. He reports side effects from finasteride, including erectile dysfunction, and slight libido impact from minoxidil.

Genetic variations influence how people respond to dutasteride for hair loss, with some benefiting more from finasteride. Dutasteride is effective for most, but genetic differences may cause it to be less effective for some.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.

Men with early male pattern baldness (MPB) may have hormonal abnormalities similar to those in women with PCOS. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

User shared progress pictures after 2 months of using 5% topical minoxidil, microneedling, and recently adding 0.01% topical finasteride. The minoxidil solution also contains caffeine, azelaic acid, retinol, adenosine, biotin, and niacinamide.

A 20-year-old male shared progress pictures after three months of using 1mg oral finasteride daily, 5% minoxidil twice daily, and a 1.5mm dermaroller weekly. He reported significant hair regrowth.

Microneedling with minoxidil significantly boosts hair growth, even for non-responders to minoxidil alone. The routine includes a 1.5mm dermaroller weekly and minoxidil twice daily, with some users adding finasteride and tretinoin.

The conversation discusses maintaining hair regrowth using minoxidil and finasteride and whether using gt20029, which degrades androgen receptors, would affect this. Fluridil, a similar treatment, can disable over 90% of active androgen receptors.

A 30-year-old shared their 7-month hair regrowth progress using topical minoxidil twice daily, 1 mg finasteride daily, and weekly microneedling. Users discussed the effectiveness of these treatments and suggested adding retinol for better results.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The user experienced hair improvement using a topical finasteride, minoxidil, and tretinoin combo, along with supplements like zinc, copper, magnesium, vitamin D3, K2, iodine, and boron. They believe these changes are due to addressing mineral deficiencies and possibly thyroid issues, despite skepticism from others.

A user shared their successful hair loss treatment using RU58841, topical minoxidil, and microneedling, noting significant improvement over three months. They chose RU58841 over finasteride due to personal preference and reported no side effects, while others discussed their experiences with different treatments and supplements.

A 26-year-old shared their 2-month progress using finasteride, minoxidil, microneedling (1mm weekly), and vitamin D3 for hair loss. They are pleased with the results.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

The post discusses the potential of upregulating aromatase to treat hair loss, suggesting that increasing CCL2 levels through Vitamin D or microneedling might help. The user questions why microneedling doesn't work for everyone, especially those with advanced hair loss.